Options
Crosstalk and Signaling Switches in Mitogen-Activated Protein Kinase Cascades
Author(s)
Date Issued
2012
Date Available
2013-11-29T10:09:44Z
Abstract
Mitogen-activated protein kinase (MAPK) cascades control cell fate decisions, such as proliferation, differentiation, and apoptosis by integrating and processing intra- and extracellular cues. However, similar MAPK kinetic profiles can be associated with opposing cellular decisions depending on cell type, signal strength, and dynamics. This implies that signaling by each individual MAPK cascade has to be considered in the context of the entire MAPK network. Here, we develop a dynamic model of feedback and crosstalk for the three major MAPK cascades; extracellular signal-regulated kinase (ERK), p38 mitogen-activated protein kinase (p38), c-Jun N-terminal kinase (JNK), and also include input from protein kinase B (AKT) signaling. Focusing on the bistable activation characteristics of the JNK pathway, this model explains how pathway crosstalk harmonizes different MAPK responses resulting in pivotal cell fate decisions. We show that JNK can switch from a transient to sustained activity due to multiple positive feedback loops. Once activated, positive feedback locks JNK in a highly active state and promotes cell death. The switch is modulated by the ERK, p38, and AKT pathways. ERK activation enhances the dual specificity phosphatase (DUSP) mediated dephosphorylation of JNK and shifts the threshold of the apoptotic switch to higher inputs. Activation of p38 restores the threshold by inhibiting ERK activity via the PP1 or PP2A phosphatases. Finally, AKT activation inhibits the JNK positive feedback, thus abrogating the apoptotic switch and allowing only proliferative signaling. Our model facilitates understanding of how cancerous deregulations disturb MAPK signal processing and provides explanations for certain drug resistances. We highlight a critical role of DUSP1 and DUSP2 expression patterns in facilitating the switching of JNK activity and show how oncogene induced ERK hyperactivity prevents the normal apoptotic switch explaining the failure of certain drugs to induce apoptosis.
Other Sponsorship
SFI 06/CE/B1129, and the European Union Seventh Frame1043 work Programme (FP7/2007-2013) ASSET project under 1044 grant agreement number FP7-HEALTH-2010-259348.
Type of Material
Journal Article
Publisher
Frontiers Media SA
Journal
Frontiers in Physiology
Volume
3
Copyright (Published Version)
2012 Frontiers Media SA
Language
English
Status of Item
Peer reviewed
This item is made available under a Creative Commons License
File(s)
Owning collection
Scopus© citations
135
Acquisition Date
Mar 28, 2024
Mar 28, 2024
Views
1570
Last Month
1
1
Acquisition Date
Mar 28, 2024
Mar 28, 2024
Downloads
388
Last Month
15
15
Acquisition Date
Mar 28, 2024
Mar 28, 2024